The Centers for Medicare & Medicaid Services this week released for comment a proposal that Medicare cover diagnostic laboratory tests that use Next Generation Sequencing for patients with a breast or ovarian cancer that may be inherited. The test used must be approved by the Food and Drug Administration, ordered by a treating physician for a patient not previously tested using NGS, and performed in a laboratory certified under the Clinical Laboratory Improvement Amendments program, among other requirements. Under the proposal, Medicare administrative contractors also could decide to cover the tests for patients with other cancers that may be inherited.

Related News Articles

Headline
Rep. Brett Guthrie, R-Ky., today addressed attendees of AHA’s 2024 Annual Membership Meeting and touched on many of the biggest issues in health care:…
Headline
The Change Healthcare cyberattack was a significant event that caught many off guard, said the Centers for Medicare & Medicaid Services Administrator…
Headline
The voluntary Episode Quality Improvement Program for specialist physicians saved Medicare $20 million in its first year, the Maryland Health Services Cost…
Headline
Commenting April 12 on a proposed rule to strengthen oversight of accrediting organizations, AHA told the Centers for Medicare & Medicaid Services it…
Headline
For future public health emergencies, the Centers for Medicare & Medicaid Services should improve how it sets Medicare rates for clinical diagnostic…
Headline
The Centers for Medicare & Medicaid Services April 4 finalized changes to the Medicare Advantage and prescription drug programs for contract year 2025…